$TWST

Finn Patrick John sold $563K of TWST

Finn Patrick John (President and COO) sold 4,046 shares of Twist Bioscience Corp (TWST) at $139.07 ($0.56M total) on 2026-08-21.

Original reporting
SEC EDGAR · Finn Patrick John
Published Aug 25, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which may be interpreted as a lack of confidence, but the amount is small.

02

Market read

A modest insider sale by a senior officer; limited immediate market impact.

03

What to watch

No 10b5-1 plan was used; the timing may be unrelated to company fundamentals.

Relevance 5/10Novelty 4/10Timing: filing reported on Aug 25, 2026 (recent)

Background

Form 4 filings disclose insider trades; investors monitor them for potential signals.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

President and COO Finn Patrick John sold 4,046 shares for $562,661, reducing his stake to 210,802 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size (~$0.56M) is modest relative to market cap, but the insider is a senior officer, which can influence sentiment.

Market effects

Minimal impact on biotech sector; only a single insider transaction.

None

None

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Finn Patrick John

    President and COO of Twist Bioscience

  • Twist Bioscience Corp

    Biotech company listed on NASDAQ

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Bond Jitters Meet Biotech Fireworks

Bond market volatility pressured stocks early in the week, with the Nasdaq dropping 2.1%. Biotech stocks surged: Moderna (MRNA) rose 177% after positive cancer trial results, and Twist Bioscience (TWST) gained 23% on AI-driven protein binder success. NVIDIA's earnings and the Jackson Hole symposium are upcoming market tests.

$TWSTHighAI 8/10

Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook

Twist Bioscience (TWST) stock rose 6.79% on strong investor optimism. The company reported Q3 revenue of $118.4M, up 23% YoY, with a 78% gross margin but negative EBIT margin and ROE. Guidance was raised to $456M-$457M for FY26, with Q4 adjusted EBITDA breakeven expected. The stock has seen strong technical performance, with resistance near $150 and support at $130-$135.

$TWSTHighAI 8/10

Why is Twist Bioscience stock surging today?

Twist Bioscience (TWST) stock rose 15.3% after Anthropic's research highlighted its role in producing AI-designed proteins. The company filed an 8-K disclosing the collaboration, which supports its AI-driven drug discovery growth narrative. Shares reached a 52-week high of $141.10.